A French company is developing a novel molecule to be used as a first or second line in the treatment of chemoresistant cancers.
The company is looking for technical cooperation agreements with biotech and pharmaceutical partners with complementary expertise.
The French company develops new, first-in-class drugs that meet unfulfilled medical needs in the fields of oncology and inflammatory diseases and notably for indications of rare diseases.
The activity is based on acquiring licensing options for technologies at an early stage of development, following the detection and early co-maturation of innovative projects derived from Universities, and then develop the technology until reaching clinical phase I/IIA and license-out to a Pharmaceutical company.
The company is developing a first-in-class new chemical entity (NCE), small molecule, which is highly specific and cytotoxic for cancer cells (nanomolar level). It has a 3-step synergic sequential mechanism of action (3 in 1 moiety):
1 - Inhibition of the translation machinery in cancer cells;
2 - Cell cycle arrest and apoptosis activation;
3 - Activation of interferon-mediated responses, sustaining apoptosis.
The company intends to develop it as a novel treatment to be integrated in the arsenal of drugs for first or second line of treatment for chemoresistant tumors, to be used alone or in combination with other drugs or within an antibody-drug conjugate (ADC) strategy.
- Type of partner sought: The company is looking for:
- all-size biotech and pharmaceutical partners with a complementary expertise in oncology drug development, in order to support the preclinical development of the anti-cancer small molecule via a co-development agreement.
- Specific area of activity of the partner: We are open to co-development agreement with Biotech/Pharma partner.